Introduction:
Human Recombinant Erythropoietin in the Medicare Patient Population
Draft Minutes
Seventeenth Meeting of the
Medical Technology and Practice Patterns Institute's
Technical Advisory Committee (TAC)
Wednesday, August 15, 2007
June 23rd 2009 Final Agenda for the Eighteenth TAC Meeting
MTPPI's Formal Initial Request for a National Coverage Determination for Recombinant human erythropoietin (rHuEPO, or epoetin) for treatment of dialysis related anemia
FDA Public Health Advisory
The maximum treatment level recommended in product labeling for all approved ESAs is to raise blood hemoglobin levels to no higher than 12 g/dL.
My Triumphant Journey as a Documentary Film Maker (Despite Kidney Disease)
Background Material -
Research Progress -
Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Zhang Y, Thamer M, Cotter D, Kaufman J, Hernan MA. Clin J Am Soc Nephrol. 2009 Mar:4(3):638-44.
Prednisone, lupus activity, and permanent organ damage. Thamer M, Hernan MA, Zhang Y, Cotter D, Petri M. J Rheumatol. 2009 Mar;36(3):560-4.
Relative mortality and epoetin alpha dose in hemodialysis patients. Cotter DJ, Thamer M, Zhang Y. Am J Kidney Dis. 2008 May;51(5):865; author reply 865-6.
The effect of epoetin dose on hematocrit. Cotter D, Zhang Y, Thamer M, Kaufman J, Hernan MA. Kidney Int. 2008 Feb;73(3):347-53.
Dose-Response -
Dose-response based on phase II study
Confounding -
Does X Really Cause Y? By Bryan Dowd and Robert Town September 2002
Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol. 2004 Oct;57(10):1086-95.
Robins JM, Hernan MA, Brumback B (2000). Marginal structural models and causal inference in epidemiology. Epidemiology, 11(5):550-560.
Bundling -
SEC. 637. DEVELOPMENT OF ESRD BUNDLING SYSTEM AND QUALITY INCENTIVE PAYMENTS.
United States Government Accountability Office (GAO) Report to the Chairman, Committee on Ways and Means, House of Representatives END-STAGE RENAL DISEASE Bundling Medicare's Payment for Drugs with Payment for All ESRD Services Would Promote Efficiency and Clinical Flexibility, November 2006
The Renal Support Network (RSN) Top 10 Concerns Regarding the Potential Bundling of ESRD Services and Its Impact on Patients
A Framework for Bundling Options Discussion Paper for the -623e Advisory Board Prepared by CMS/ORDI/MDPG May 24, 2005MMA
MedPAC Outpatient Dialysis services payment system Payment Basics September 2006
Ways and Means Truth Squad: Anemia Management Care
Future TAC Meeting topics -
The 2005 Nationwide Blood Collection and Utilization Survey
End Stage Renal Disease (ESRD) Quality Initiative Quality Measures Clinical Performance Measures Consumer Qs and As for Dialysis Facility Compare